Cytokine therapy in combination treatment of colorectal cancer

Abstract

Background. Treatment of colorectal cancer in late lines of drug therapy presents significant challenges, since the arsenal of antitumor therapy options is limited. The possibility of using cytokinogenetic therapy drugs is attractive for potentiating the effect of re-administered cytostatics.

Objective. To evaluate the efficacy and safety of cytokinogenetic therapy in combination with cytostatic therapy in a patient with stage IV progressive colon cancer in the late line of antitumor treatment.

Material and methods. A 62-year-old patient was observed, admitted with a diagnosis of primary multiple synchronous colon cancer: transverse colon cancer, usT3N2M1b (liver), surgery (09/27/2022), 4 lines of therapy (FOLFOX-6, FOLFIRI + bevacizumab, regorafinib, cetuximab), progression, rectal cancer pT2N0M0, surgery (06/18/2020, 09/27/2022). During the examination, magnetic resonance imaging (MRI) with contrast enhancement was used.

Results. The patient noted an improvement in his well-being after three courses of cytokinogenetic therapy, and after the 8th course he was able not only to do his usual housework and get to the hospital on his own, but also began to do his professional activities a little. The use of antitumor therapy according to the XELOX scheme (5th line) in combination with cytokinogenetic therapy was not accompanied by significant toxicity. According to MRI data, partial regression of tumor foci was achieved.

Conclusion. The combined use of polychemotherapy according to the XELOX scheme and cytokinogenetic therapy drugs made it possible to achieve partial regression of a previously progressing tumor and increase the patient's life expectancy.